UCB initiated with a Buy at Goldman Sachs

Goldman Sachs analyst Rajan Sharma initiated coverage of UCB (UCBJF) with a Buy rating and EUR 250 price target The firm views UCB as a “rare opportunity” within European biopharma, offering a “significant blockbuster” launch through Bimzelx at a compelling entry point.